Structure-Based Design of Potent and Highly Selective NUAK1 Inhibitors by Exploiting a Unique Glutamate Switch for the Prevention of Tumor Growth, Migration, and Invasion
Authors:
- 19 March 2026
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (7) , 7817-7838
Abstract
NUAK1, an AMPK-related kinase overexpressed in cancers, plays a crucial role in tumor metastasis and cell survival, making it an attractive cancer therapeutic target. Herein, we report potent, selective NUAK1 inhibitors via structure-guided repurposing of a covalent JAK3 inhibitor. By capitalizing on the critical structural difference─Cys909 in JAK3 versus Glu139 in NUAK1─we substituted the electrophilic warhead with glutamate-favoring moieties, a modification that confers selective NUAK1 targeting. Supporting this design rationale, cocrystal structures verify the specific engagement of these moieties with the Glu139 residue of NUAK1. Among the synthesized analogs, candidate compound 10i exhibits subnanomolar NUAK1 inhibition (IC50 = 0.49 nM) and kinome-wide selectivity. Besides, 10i suppresses proliferation, migration, and invasion of triple-negative breast cancer cells, reverses EMT markers, and shows robust antitumor efficacy in mouse xenografts. This study provides a promising lead and validates Glu139 as an anchor for selective NUAK1 targeting.Keywords
Funding Information
- National Natural Science Foundation of China (22521104)
- National Natural Science Foundation of China (82173650)
- National Natural Science Foundation of China (82473758)
- National Natural Science Foundation of China (82530108)
- Hangzhou Institute of Medicine, Chinese Academy of Sciences
This publication has 33 references indexed in Scilit:
- Chemical Adaptation in Drug Discovery: The Medicinal Chemistry Journey of Olverembatinib and Limertinib in Overcoming Kinase Drug ResistanceAccounts of Chemical Research, 2025
- NUAK1 activates STAT5/GLI1/SOX2 signaling to enhance cancer cell expansion and drives chemoresistance in gastric cancerCell Reports, 2024
- p-tau Ser356 is associated with Alzheimer’s disease pathology and is lowered in brain slice cultures using the NUAK inhibitor WZ4003Acta Neuropathologica, 2024
- Discovery of a novel NUAK1 inhibitor against pancreatic cancerBiomedicine & Pharmacotherapy, 2022
- Reduction of Nuak1 Decreases Tau and Reverses Phenotypes in a Tauopathy Mouse ModelNeuron, 2016
- ARK5 promotes doxorubicin resistance in hepatocellular carcinoma via epithelial–mesenchymal transitionCancer Letters, 2016
- Overexpression of ARK5 is associated with poor prognosis in hepatocellular carcinomaTumor Biology, 2013
- ARK5 promotes glioma cell invasion, and its elevated expression is correlated with poor clinical outcomeEuropean Journal of Cancer, 2013
- ARK5 is associated with the invasive and metastatic potential of human breast cancer cellsJournal of Cancer Research and Clinical Oncology, 2011
- A new serine/threonine protein kinase,Omphk1, essential to ventral body wall formationDevelopmental Dynamics, 2006